Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. (Q54420009)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

colorectal cancer

1 reference

based on heuristic

inferred from title

7

object named as

Yasushi Yatabe

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

author name string

Tomoya Yokota

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

Noriko Shibata

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

Takashi Ura

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

Daisuke Takahari

4

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

Kohei Shitara

5

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

Kei Muro

6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

publication date

19 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

Translational Research

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

156

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

98-105

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Somatic mutations of EGFR in colorectal cancers and glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Disproportionate representation ofKRAS gene mutation in atypical adenomatous hyperplasia, but even distribution ofEGFR gene mutation from preinvasive to invasive adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

A high frequency of sequence alterations is due to formalin fixation of archival specimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Somatic mutations of epidermal growth factor receptor in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Assessing EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2010.05.007

7 January 2021

Identifiers

10.1016/J.TRSL.2010.05.007

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/20627194

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54420009&oldid=1367502260"